May 21 Biotech Update

It is a similar start to the trading day with the market sort of flat with the sector a little lower (with notable exceptions which will be discussed below). It.

May 20 Biotech Update

The market was off to a benign start but the sector seemed to take it on the chin (albeit on generally light volume). I am not sure why the selling.

May 19 Biotech Update

A mixed start to the morning with some red and green. It seems to me that the market generally wants to move higher but no one seems to have high.

May 18th Biotech Update

The sector seems to be treading water this morning if not slightly outperforming the broader market. There seems to be a tug of war of wanting to be positioned into.

Catalyst Watch – Vol. 3, Edition 7 (5/15/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

May 12 Biotech Update

The sector is being hit this morning, although it is really the market that is weak and taking the sector with it. Yesterday the sector did a good job holding.

May 11 Biotech Update

It is a good start to the week which is interesting as we have little news and a lack of M&A. I was curious as to how the sector would.

May 8 Biotech Update

I wish I had more time to write this week but it has been too busy. The sector is obviously doing well and perhaps we have bottomed but at the.

May 6 Biotech Update

Well, we finally get another deal and it is pretty telling how the sector reacted. Obviously there is a tailwind but it is not universal and we need to see.

Quick update from TRIL Presentation in Toronto

  Trillium Therapeutics Inc. (TRIL) – Nasdaq   Trillium Therapeutics presented at Bloomburton-2015 Healthcare Investor Conference in Toronto on May 5th, the speaker Dr. Rob Uger, TRIL’s Chief Scientific Officer (CSO) was.

May 5 Biotech Update

So clearly the strength later in the day did not play out yesterday and it ended up being yet another day with a strong open and a move that was.

May 4 Biotech Update

It is a decent start to the day with a positive open. The longer that we do not pullback the more pressure it will place on those who were short.

Chimera Research Group Catalyst Summary for April 2015

At the end of each month Chimera Research Group provides you with a monthly summary of ten notable catalysts/events that have been completed during the past month. APRIL 2015: Gilead.

May 1 Biotech Update

What a difference a day makes. Yesterday nobody wanted to buy a biotech and there was nothing that could ever happen that could reverse the selling. A giant GILD beat.

Catalyst Watch – Vol. 3, Edition 6 (4/30/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

April 29 Biotech Update

This has to be a quick note as this morning is busy but clearly the market is teetering. The bounce this morning is nice but we need a lot more.

April 28 Biotech Update

So it ended up being a bad start to the week with a significant drop straight down to support with follow through early this morning. The sector seemed to find.

The Week Ahead in Earnings

A second busy week of earnings is due out in the space this week. We will see 3 of the 4 remaining large caps report (Gilead, Celgene, Vertex) and a.

April 27 Biotech Update

The sector has to deal with both some negative headlines and the lack of any deals on Merger Monday but it is difficult to read too much into the action.

April 24 Biotech Update

Some news to talk about today with interesting implications and I will try to cover most of them. The sector seems to be lagging early despite some business development news.

April 22 Biotech Update

Another busy day so I have to keep this very short as I am trying to squeeze this in between meetings. In general, the sector seems to be doing fine.

April 21 Biotech Update

A lot of news to cover and I want to get to it all, so maybe a little less detail and more topics today and I will circle back to.

April 17 Biotech Update

The sector is certainly weak to start the day and obviously this seems driven by the macro. It was not immediately clear to me the trigger for the selling. Was.

Catalyst Watch – Vol. 3, Edition 5 (4/17/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

April 15 Biotech Update

It is a busy day so I am going to try and keep this short but every time I write that it seems like I write the same amount if.

Quick Note on GWPH

Embargoed Data was released yesterday in an announcement from AAN regarding GW Pharmaceuticals’ Epidiolex study: https://www.aan.com/PressRoom/Home/PressRelease/1364 This paragraph summarizes the Key Takeaway: “For the 137 people who completed the 12-week.

April 14 Biotech Update

A weak start to the day that essentially appears to be a continuation from the late selling yesterday. It still seems to be the case that large caps are underperforming.

April 13 Biotech Update

Happy merger Monday- well, happy Monday at least. The sector is off to a good start this week despite another dearth of deals this morning. It does worry me a.

April 10 Biotech Update

A good opening to the sector and large caps but the move was almost immediately faded (especially the large caps). Yesterday ended better than the past, so perhaps the sector.

CYNAF is OFF the Mark

Cynapsus is developing a sublingual film formulation of apomorphine for the treatment of acute “Off” episodes in patients with Parkinson’s Disease resulting from long term use of Levodopa. While Levodopa.

April 9th Biotech Update

The market is choppy this morning so it is difficult to read anything into the price action. I am growing slightly more constructive on the near term of the sector.

Browsing 31 / 1 articles